Carbon-11-Labeled Methionine PET/CT in Patients With FDG-Occult Multiple Myeloma: A Prospective Pilot Study.

In a pilot study (ClinicalTrials.gov NCT02646085), seven patients with treated multiple myeloma and negative FDG PET/CT underwent amino acid imaging with C-methionine PET/CT. In five participants, C-methionine PET/CT showed focal uptake corresponding with lytic lesions; two to 18 lesions were found (SUV, 2.8-6.4). Findings indicated a potential role for C-methionine PET/CT in detecting residual disease after negative FDG PET/CT, thereby guiding further treatment.